Immunic, Inc. Participates in Investor Conferences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy IMUX?
Source: PRnewswire
- Investor Conference Participation: Immunic, Inc. will participate in several investor conferences in March, with management including Dr. Vitt, Mr. Tardio, and VP of Investor Relations Jessica Breu engaging in one-on-one meetings to enhance investor relations and transparency.
- Clinical Trial Progress: The company's lead program, vidofludimus calcium (IMU-838), is currently in phase 3 trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, which could significantly impact the company's market performance.
- Innovative Drug Mechanism: IMU-838 acts as a first-in-class Nurr1 activator, combining neuroprotective and anti-inflammatory effects by selectively inhibiting dihydroorotate dehydrogenase (DHODH), showcasing its potential in treating various neurological and gastrointestinal diseases.
- Future Development Directions: The company is also developing new molecules like IMU-856 and IMU-381, with the former aimed at restoring intestinal barrier function and the latter targeting neurological and autoimmune diseases, indicating Immunic's ongoing innovation and market expansion strategy in the biotech sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMUX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMUX
Wall Street analysts forecast IMUX stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.020
Low
3.00
Averages
4.25
High
8.00
Current: 1.020
Low
3.00
Averages
4.25
High
8.00
About IMUX
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immunic, Inc. Participates in Investor Conferences
- Investor Conference Participation: Immunic, Inc. will participate in several investor conferences in March, with management including Dr. Vitt, Mr. Tardio, and VP of Investor Relations Jessica Breu engaging in one-on-one meetings to enhance investor relations and transparency.
- Clinical Trial Progress: The company's lead program, vidofludimus calcium (IMU-838), is currently in phase 3 trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, which could significantly impact the company's market performance.
- Innovative Drug Mechanism: IMU-838 acts as a first-in-class Nurr1 activator, combining neuroprotective and anti-inflammatory effects by selectively inhibiting dihydroorotate dehydrogenase (DHODH), showcasing its potential in treating various neurological and gastrointestinal diseases.
- Future Development Directions: The company is also developing new molecules like IMU-856 and IMU-381, with the former aimed at restoring intestinal barrier function and the latter targeting neurological and autoimmune diseases, indicating Immunic's ongoing innovation and market expansion strategy in the biotech sector.
See More
Immunic, Inc. to Participate in Investor Conferences
- Investor Conference Schedule: Immunic, Inc. will participate in the Leerink Partners Global Healthcare Conference from March 8-11, where CEO Daniel Vitt, Ph.D., and COO Jason Tardio will engage in a fireside chat on March 11, potentially increasing investor interest and enhancing company visibility.
- One-on-One Meeting Opportunities: During the conference, Immunic's executive team will hold one-on-one meetings with investors, providing in-depth discussions about the business and products, which could bolster investor confidence and facilitate potential capital inflows.
- Clinical Trial Progress: The company's lead development program, vidofludimus calcium (IMU-838), is currently in Phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, which could significantly impact the company's future market performance.
- New Therapy Development: New molecules like IMU-856 and IMU-381 are under development to address various neurological and gastrointestinal diseases, and successful launches will further solidify Immunic's leadership in the biotechnology sector and drive long-term growth.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Investor Focus: Analysts' opinions are particularly crucial when considering the purchase of CRWD stock, as their ratings and price targets can directly impact short-term stock performance and investor confidence.
- Source of Updates: Comprehensive information on analyst rating changes, including upgrades and downgrades, has been published on Benzinga's analyst ratings page, providing investors with a holistic view of the market.
- Market Reaction Potential: Changes in analyst ratings may trigger market volatility, prompting investors to closely monitor these shifts to timely adjust their investment strategies and risk management practices.
See More
Immunic Reports FY 2025 Earnings with Positive Cash Outlook
- Earnings Highlights: Immunic reported a FY 2025 GAAP EPS of -$0.62, beating expectations by $0.05, indicating improvements in financial management despite ongoing losses.
- Cash Position: As of December 31, 2025, Immunic had approximately $15.5 million in cash and cash equivalents, providing a short-term liquidity buffer that ensures operational stability in the coming months.
- Funding Strategy: The company raised approximately $187 million in net cash from a private placement in February 2026, enabling it to fund operations into late 2027, which bolsters market confidence in its sustainability.
- Market Reaction: Following the announcement of a $400 million private placement, Immunic's stock price rose, reflecting investor optimism about the company's future, particularly in light of leadership transitions.
See More
Immunic Secures $400 Million for MS Trials and Transition
- Successful Financing: Immunic has successfully completed an oversubscribed private placement of up to $400 million, with $200 million in upfront gross proceeds, which positions the company for a confident transition into a fully integrated commercial-stage entity, reflecting investor confidence in its multiple sclerosis (MS) treatment program.
- Clinical Trial Progress: The phase 3 ENSURE trials for Immunic's lead asset, vidofludimus calcium (IMU-838), in relapsing multiple sclerosis (RMS) are expected to yield top-line data by the end of 2026, providing critical insights for future drug applications and market entry.
- New Drug Application Plans: The company plans to submit a New Drug Application (NDA) for RMS in the U.S. by mid-2027, with a targeted regulatory approval date in 2028, which will prepare for the potential launch of vidofludimus calcium and enhance its competitive position in the global MS market projected to exceed $30 billion.
- Innovative Mechanism of Action: Vidofludimus calcium, as a first-in-class Nurr1 activator, aims to improve neuronal survival and function through direct neuroprotective effects and selective DHODH inhibition, potentially offering a best-in-class benefit-risk profile that could unlock significant commercial opportunities in MS treatment.
See More
Immunic Secures $200 Million Financing to Advance Multiple Sclerosis Research
- Successful Financing: Immunic has successfully completed an oversubscribed private placement of up to $400 million, with $200 million in initial gross proceeds, which is expected to fund its multiple sclerosis (MS) projects and facilitate the company's transition to a commercial-stage organization.
- Clinical Trial Progress: Top-line data from the ENSURE-1 and ENSURE-2 Phase 3 trials for multiple sclerosis is anticipated by the end of 2026, laying the groundwork for future drug applications and market launches, with potential regulatory approval expected in 2028.
- New Drug Application Plans: The company plans to submit a New Drug Application (NDA) in mid-2027 for vidofludimus calcium in the U.S. market, which is expected to significantly enhance its competitiveness in the projected $30 billion global multiple sclerosis market.
- Board Changes: Immunic has appointed a new interim chairperson of the board and initiated a search for a new CEO with commercial expertise to support the company's further development in the multiple sclerosis field.
See More
Immunic, Inc. Participates in Investor Conferences
- Investor Conference Participation: Immunic, Inc. will participate in several investor conferences in March, with management including Dr. Vitt, Mr. Tardio, and VP of Investor Relations Jessica Breu engaging in one-on-one meetings to enhance investor relations and transparency.
- Clinical Trial Progress: The company's lead program, vidofludimus calcium (IMU-838), is currently in phase 3 trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, which could significantly impact the company's market performance.
- Innovative Drug Mechanism: IMU-838 acts as a first-in-class Nurr1 activator, combining neuroprotective and anti-inflammatory effects by selectively inhibiting dihydroorotate dehydrogenase (DHODH), showcasing its potential in treating various neurological and gastrointestinal diseases.
- Future Development Directions: The company is also developing new molecules like IMU-856 and IMU-381, with the former aimed at restoring intestinal barrier function and the latter targeting neurological and autoimmune diseases, indicating Immunic's ongoing innovation and market expansion strategy in the biotech sector.
See More
Immunic, Inc. to Participate in Investor Conferences
- Investor Conference Schedule: Immunic, Inc. will participate in the Leerink Partners Global Healthcare Conference from March 8-11, where CEO Daniel Vitt, Ph.D., and COO Jason Tardio will engage in a fireside chat on March 11, potentially increasing investor interest and enhancing company visibility.
- One-on-One Meeting Opportunities: During the conference, Immunic's executive team will hold one-on-one meetings with investors, providing in-depth discussions about the business and products, which could bolster investor confidence and facilitate potential capital inflows.
- Clinical Trial Progress: The company's lead development program, vidofludimus calcium (IMU-838), is currently in Phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, which could significantly impact the company's future market performance.
- New Therapy Development: New molecules like IMU-856 and IMU-381 are under development to address various neurological and gastrointestinal diseases, and successful launches will further solidify Immunic's leadership in the biotechnology sector and drive long-term growth.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Investor Focus: Analysts' opinions are particularly crucial when considering the purchase of CRWD stock, as their ratings and price targets can directly impact short-term stock performance and investor confidence.
- Source of Updates: Comprehensive information on analyst rating changes, including upgrades and downgrades, has been published on Benzinga's analyst ratings page, providing investors with a holistic view of the market.
- Market Reaction Potential: Changes in analyst ratings may trigger market volatility, prompting investors to closely monitor these shifts to timely adjust their investment strategies and risk management practices.
See More
Immunic Reports FY 2025 Earnings with Positive Cash Outlook
- Earnings Highlights: Immunic reported a FY 2025 GAAP EPS of -$0.62, beating expectations by $0.05, indicating improvements in financial management despite ongoing losses.
- Cash Position: As of December 31, 2025, Immunic had approximately $15.5 million in cash and cash equivalents, providing a short-term liquidity buffer that ensures operational stability in the coming months.
- Funding Strategy: The company raised approximately $187 million in net cash from a private placement in February 2026, enabling it to fund operations into late 2027, which bolsters market confidence in its sustainability.
- Market Reaction: Following the announcement of a $400 million private placement, Immunic's stock price rose, reflecting investor optimism about the company's future, particularly in light of leadership transitions.
See More
Immunic Secures $400 Million for MS Trials and Transition
- Successful Financing: Immunic has successfully completed an oversubscribed private placement of up to $400 million, with $200 million in upfront gross proceeds, which positions the company for a confident transition into a fully integrated commercial-stage entity, reflecting investor confidence in its multiple sclerosis (MS) treatment program.
- Clinical Trial Progress: The phase 3 ENSURE trials for Immunic's lead asset, vidofludimus calcium (IMU-838), in relapsing multiple sclerosis (RMS) are expected to yield top-line data by the end of 2026, providing critical insights for future drug applications and market entry.
- New Drug Application Plans: The company plans to submit a New Drug Application (NDA) for RMS in the U.S. by mid-2027, with a targeted regulatory approval date in 2028, which will prepare for the potential launch of vidofludimus calcium and enhance its competitive position in the global MS market projected to exceed $30 billion.
- Innovative Mechanism of Action: Vidofludimus calcium, as a first-in-class Nurr1 activator, aims to improve neuronal survival and function through direct neuroprotective effects and selective DHODH inhibition, potentially offering a best-in-class benefit-risk profile that could unlock significant commercial opportunities in MS treatment.
See More
Immunic Secures $200 Million Financing to Advance Multiple Sclerosis Research
- Successful Financing: Immunic has successfully completed an oversubscribed private placement of up to $400 million, with $200 million in initial gross proceeds, which is expected to fund its multiple sclerosis (MS) projects and facilitate the company's transition to a commercial-stage organization.
- Clinical Trial Progress: Top-line data from the ENSURE-1 and ENSURE-2 Phase 3 trials for multiple sclerosis is anticipated by the end of 2026, laying the groundwork for future drug applications and market launches, with potential regulatory approval expected in 2028.
- New Drug Application Plans: The company plans to submit a New Drug Application (NDA) in mid-2027 for vidofludimus calcium in the U.S. market, which is expected to significantly enhance its competitiveness in the projected $30 billion global multiple sclerosis market.
- Board Changes: Immunic has appointed a new interim chairperson of the board and initiated a search for a new CEO with commercial expertise to support the company's further development in the multiple sclerosis field.
See More
